CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 50 enrolled
Drug / intervention
Dronabinol +1 moredrug
Likely dose
Dronabinol 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03530800
NCT03530800Phase 3Completed

A Double-Blind, Placebo-Controlled Study of Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors

University of Chicago·interventional·Posted May 21, 2018·Updated Jun 2, 2022

In Brief

A Phase 3 clinical trial evaluating Dronabinol and Placebo for Trichotillomania and Skin-Picking. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The goal of the proposed study is to evaluate the efficacy and safety of dronabinol in trichotillomania and other body-focused repetitive behaviors such as skin-picking disorder. 50 subjects with DSM-5 trichotillomania or skin-picking disorder will receive 10 weeks of double-blind dronabinol or placebo. The hypothesis to be tested is that dronabinol will be effective and well tolerated in patients with trichotillomania and/or skin-picking disorder compared to placebo. The proposed study will provide needed data on the treatment of disabling disorders that currently lacks a clearly effective treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMay 21, 2018
Enrollment StartOct 1, 2018
Primary CompletionJul 20, 2021
Study CompletionNov 1, 2021
TodayJul 1, 2026
Enrollment to primary: 2.8 yearsPosted 8.1 years ago

Interventions

Dronabinoldrug

Dronabinol for 10 weeks (5mg per day first 2 weeks, 10mg per day second two weeks, 15mg per day last six weeks)

Placebodrug

Placebo for 10 weeks